Connect Biopharma Holdings (CNTB) Total Non-Current Liabilities (2020 - 2026)

Connect Biopharma Holdings has reported Total Non-Current Liabilities for 7 years, with the latest figure at $17.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 89.23% year-over-year to $17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (up 89.23% YoY) and the FY2025 annual result came in at $14.0 million, up 64.75% from the prior year.
• Total Non-Current Liabilities improved to $17.3 million in Q1 2026 per CNTB's latest filing, from $14.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $17.3 million in Q1 2026 and troughed at $467000.0 in Q2 2024.
• A 5-year average of $6.9 million and a median of $8.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 53.94% in 2023, then surged 2311.35% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $877791.3 in 2022, then slumped by 33.36% to $585000.0 in 2023, then soared by 1350.6% to $8.5 million in 2024, then soared by 64.75% to $14.0 million in 2025, then grew by 23.97% to $17.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $17.3 million, $14.0 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.